ReviewWorld journal of gastroenterology2016
Antibody markers in the diagnosis of inflammatory bowel disease.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.Health technology assessment (Winchester, England) · 2021Pooled it
- Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies.Immunologic research · 2019Pooled it
- ACG Clinical Guideline: Management of Crohn's Disease in Adults.The American journal of gastroenterology · 2018Guideline
- Serological profiling of Crohn's disease and ulcerative colitis patients reveals anti-microbial antibody signatures.World journal of gastroenterology · 2022Trial
- Article
- Review
- REGULATION OF COLONIC MACROPHAGES AND TYPE-17 AND REGULATORY T CELLS IN DSS-COLITIS BY IBD-ASSOCIATED TRANSCRIPTION FACTOR, CREM.bioRxiv : the preprint server for biology · 2026Article
- Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.Journal for immunotherapy of cancer · 2026Article
- Depletion of IgG-producing plasma cells in the colon by treatment of proteasome inhibitor ameliorates chronic DSS-induced colitis in mice.Scientific reports · 2026Article
- Mechanisms of inflammation in premature ovarian insufficiency and advances in therapeutic studies.Frontiers in immunology · 2026Review
- Mechanisms and impact of long COVID: pathophysiology, neuropsychiatric effects and vaccination.Frontiers in immunology · 2026Review
- Divergent T Cell Phenotypes Define Pediatric Crohn's Disease and Ulcerative Colitis.medRxiv : the preprint server for health sciences · 2025Article
- Review
- Antineutrophil Cytoplasmic Autoantibodies Specific to Bactericidal/Permeability-Increasing Protein: A Cross-Road Between Prolonged Gram-Negative Bacterial Infections and Ulcerative Colitis/Primary Sclerosing Cholangitis.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Autoantibody Profiling in Ulcerative Colitis: Identification of Early Immune Signatures and Disease-Associated Antigens for Improved Diagnosis and Monitoring.International journal of molecular sciences · 2025Article
- Disease-specific B cell clones are shared between patients with Crohn's disease.Nature communications · 2025Article
- Exploring gut microbiota as a novel therapeutic target in Crohn's disease: Insights and emerging strategies.World journal of gastroenterology · 2025Review
- Inflammatory bowel disease patients believe cannabis and cannabidiol oil relieve symptoms.Academia medicine · 2025Article
- Unraveling the complexity of ulcerative colitis: insights into cytokine dysregulation and targeted therapies.EXCLI journal · 2025Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic intestinal inflammation of unknown etiology. The diagnosis of IBD is based on endoscopic, radiologic and histopathologic criteria. Recently, the search for a noninvasive marker that could augment or replace part of this diagnostic process has become a focus of IBD research. In this review, antibody markers, including microbial antibodies, autoantibodies and peptide antibodies, will be described, focusing on their common features. At present, no single marker with qualities that are satisfactory for the diagnosis and treatment of IBD has been identified, although panels of some antibodies are being evaluated with keen interest. The discovery of novel IBD-specific and sensitive markers is anticipated. Such markers could minimize the use of endoscopic and radiologic examinations and could enable clinicians to implement individualized treatment plans designed to improve the long-term prognosis of patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.